Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Pilot Study of rhBMP-2/ACS/LT-CAGE® for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

1. august 2013 opdateret af: Medtronic Spinal and Biologics

A Feasibility Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

This study is designed to evaluate the feasibility of recombinant human bone morphogenetic protein-2 and absorbable collagen sponge with the tapered interbody fusion device (LT-CAGE® ) for anterior lumbar interbody fusion in patients with degenerative disc disease.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

14

Fase

  • Ikke anvendelig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Has degenerative disc disease as noted by back pain of discogenic origin with degeneration of the disc confirmed by radiographic studies.
  2. Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW, 1932.)
  3. Has single level symptomatic degenerative involvement from L2 to S1.
  4. Is between the ages of 18 and 65, inclusive, at the time of surgery.
  5. Is willing to comply with the study plan and sign the Patient Informed Consent Form.
  6. Has not responded to conservative treatment for a period of 5 months.
  7. If of child-bearing potential, subject is non-pregnant (documented by a negative Pregnancy test within 72 hours of surgery), non-nursing female who agrees to use adequate contraception for 16 weeks following surgery

Exclusion Criteria:

  1. Has spinal condition other than symptomatic degenerative disc disease at the involved surgical level.
  2. Had previous anterior surgical procedures at the involved spinal level.
  3. Has a condition which requires postoperative medications that interfere with fusion such as steroids or nonsteroidal anti-inflammatory drugs. (This does not include low dose aspirin for prophylactic anticoagulation.)
  4. Has osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
  5. Has circulatory problems, such as thrombophlebitis, lymphedema, or vascular deficiency at the implant site.
  6. Has symptomatic cardiac disease.
  7. Has presence of active malignancy or history of cancer in the past 5 years.
  8. Has overt or active infection.
  9. Is obese, i.e., weight greater than 40% over ideal for their age and height.
  10. Has fever (temperature > 101°F oral).
  11. Has local inflammatory signs indicative of infection.
  12. Has a documented metal allergy or intolerance.
  13. Is involved in a worker's compensation or unresolved spinal litigation case.
  14. Is mentally incompetent (either documented or in the opinion of the investigator).
  15. Has psychogenic magnification of pain (in the opinion of the investigator).
  16. Is a prisoner.
  17. Is pregnant.
  18. Is an alcohol and/or substance abuser.
  19. Requires bone growth stimulation in the lumbar spine.
  20. Is a tobacco user at the time of surgery.
  21. Patient has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate).
  22. Patient has a history of autoimmune disease (systemic lupus erythematosus or dermatomyositis).
  23. The subject has a history of exposure to injectable collagen implants.
  24. Patient's history includes hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.
  25. Patient has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation.
  26. Patient has received any previous exposure to BMP.
  27. The patient requires allograft or bone substitute as part of treatment.
  28. Patient has history of endocrine or metabolic disorder known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta).
  29. Patient in the physician's opinion, would not be a good candidate for this surgical procedure.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: rhBMP-2/ACS
rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
Andre navne:
  • Rekombinant humant knoglemorfogenetisk protein-2
Aktiv komparator: Autograft
LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
Andre navne:
  • Autogent knogletransplantation

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Fusion
Tidsramme: 24 month
24 month

Sekundære resultatmål

Resultatmål
Tidsramme
Pain Assessment (Oswestry Disability Index, ODI)
Tidsramme: 24 month
24 month
Neurological Status Assessment
Tidsramme: 24 month
24 month
Health status assessment (SF-36)
Tidsramme: 24 month
24 month

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. januar 1997

Primær færdiggørelse (Faktiske)

1. september 1999

Studieafslutning (Faktiske)

1. september 1999

Datoer for studieregistrering

Først indsendt

12. december 2011

Først indsendt, der opfyldte QC-kriterier

12. december 2011

Først opslået (Skøn)

14. december 2011

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

2. august 2013

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. august 2013

Sidst verificeret

1. december 2011

Mere information

Begreber relateret til denne undersøgelse

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Degeneration af Lumbal Intervertebral Disc

Kliniske forsøg med rhBMP-2/ACS/LT-CAGE® Device

3
Abonner